...
首页> 外文期刊>American Journal of Hematology >MECOM MECOM , HBS1L‐MYB HBS1L‐MYB , THRB‐RARB, JAK2 THRB‐RARB, JAK2 , and TERT TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients
【24h】

MECOM MECOM , HBS1L‐MYB HBS1L‐MYB , THRB‐RARB, JAK2 THRB‐RARB, JAK2 , and TERT TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients

机译:Mecom Mecom,HBS1L-MYB HBS1L-MYB,THRB-RARB,JAK2 THRB-RARB,JAK2和TERT TERT多态性定义遗传易感性对Myeloproiferative肿瘤的遗传易感性:939例患者的研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Abstract Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) are classical myeloproliferative neoplasms (MPN), characterized by specific somatic mutations in JAK2 , CALR or MPL genes. JAK2 46/1 and TERT rs2736100 polymorphisms are known to significantly predispose to MPN. This study aimed to establish the additional contribution of the recently described MECOM rs2201862, HBS1L‐MYB rs9376092 and THRB‐RARB rs4858647 polymorphisms to the occurrence of MPN. These three polymorphisms, along with JAK2 46/1 and TERT rs2736100 were genotyped in 939 MPN patients (454 with ET, 337 with PV and 148 with PMF) and 483 controls. MECOM rs2201862 associated significantly with each MPN entity, except for ET, and with all major molecular sub‐types, especially those CALR ‐mutated (OR?=?1.4; 95% CI?=?1.1‐1.8; P ‐value?=?.005). HBS1L‐MYB rs9376092 associated only with JAK2 V617F‐mutated ET (OR?=?1.4; 95% CI?=?1.1‐1.7; P ‐value?=?.003). THRB‐RARB rs4858647 had a weak association with PMF only (OR?=?1.5; 95% CI?=?1‐2.1; P ‐value?=?.04). Surprisingly, JAK2 46/1 haplotype was associated significantly not only with JAK2 V617F‐mutated MPN, but also with CALR ‐mutated MPN (OR?=?1.4; 95% CI?=?1.1‐1.8; P ‐value?=?.01). TERT rs2736100 was associated equally strong with all MPN, regardless of phenotype or molecular sub‐type. In conclusion, JAK2 46/1, TERT rs2736100 and MECOM rs2201862 are the chief predisposing polymorphisms to MPN.
机译:摘要多胆血症Vera(PV),基本血小盲症(ET)和原发性骨髓纤维化(PMF)是典型的髓样肿瘤(MPN),其特征在于JAK2,CALR或MPL基因中的特异性体细胞突变。已知JAK2 46/1和TERT RS2736100多态性明显倾向于MPN。本研究旨在建立最近描述的MECOM RS2201862,HBS1L-MYB RS9376092和THRB-RARB RS4858647多态性的额外贡献,以发生MPN的发生。这三种多态性以及JAK2 46/1和TERT RS2736100在939名MPN患者中进行了基因分型(454,含有PV和148,PMF的PV和148)和483个对照。 Mecom RS2201862与每个MPN实体显着相关,除ET外,以及所有主要的分子子类型,尤其是那些Calr - 或?=?1.4; 95%CI?=?1.1-1.8; P -Value?=? .005)。 HBS1L-MYB RS9376092仅用JAK2 V617F突变ET(或?=?1.4; 95%CI?=?1.1-1.7; P -Value?=Δ= 003)。 THRB-RARB RS4858647仅与PMF相关联(或?=?1.5; 95%CI?=?1-2.1; P -VALUE?= 04)。令人惊讶的是,JAK2 46/1单倍型不仅与JAK2 V617F突变的MPN有显着相关,还与Calr-Mutated MPN(或?=?1.4; 95%CI?=?1.1-1.8; P -Value?= ?. 01)。 TERT RS2736100与所有MPN相关联,无论表型或分子亚型如何,都与所有MPN相关联。总之,JAK2 46/1,TERT RS2736100和MECOM RS2201862是MPN的主要易感性多态性。

著录项

  • 来源
    《American Journal of Hematology》 |2018年第1期|共7页
  • 作者单位

    Department of Medical GeneticsIuliu Ha?ieganu University of Medicine and PharmacyCluj‐Napoca Romania;

    Department of GeneticsCenter for Advanced Medical and Pharmaceutical Research University of;

    Department of HematologyIon Chiricu?? Cancer Institute Iuliu Ha?ieganu University of Medicine and;

    Department of Medical GeneticsIuliu Ha?ieganu University of Medicine and PharmacyCluj‐Napoca Romania;

    Department of GeneticsIon Chiricu?? Cancer InstituteCluj‐Napoca Romania;

    Department of GeneticsIon Chiricu?? Cancer InstituteCluj‐Napoca Romania;

    Department of Pharmacology and ToxicologyIuliu Ha?ieganu University of Medicine and PharmacyCluj;

    Department of GeneticsCenter for Advanced Medical and Pharmaceutical Research University of;

    Department of HematologyIon Chiricu?? Cancer Institute Iuliu Ha?ieganu University of Medicine and;

    Department of HematologyColentina HospitalBucharest Romania;

    Department of Pharmacology and ToxicologyIuliu Ha?ieganu University of Medicine and PharmacyCluj;

    Department of HematologyColentina HospitalBucharest Romania;

    Department of HematologyIon Chiricu?? Cancer Institute Iuliu Ha?ieganu University of Medicine and;

    Department of HematologyEmergency County Hospital Lucian Blaga UniversitySibiu Romania;

    Department of HematologyCol?ea Hospital Carol Davila University of Medicine and PharmacyBucharest;

    Department of HematologyUniversity of Medicine and PharmacyRomania T?rgu‐Mure?;

    Department of HematologyCol?ea Hospital Carol Davila University of Medicine and PharmacyBucharest;

    Department of HematologyVictor Babe? University of Medicine and PharmacyTimi?oara Romania;

    Department of HematologyEmergency County Hospital Lucian Blaga UniversitySibiu Romania;

    Department of Medical GeneticsIuliu Ha?ieganu University of Medicine and PharmacyCluj‐Napoca Romania;

    Department of HematologyIon Chiricu?? Cancer Institute Iuliu Ha?ieganu University of Medicine and;

    Department of HematologyEmergency County HospitalDeva Romania;

    Department of HematologyEmergency County HospitalBaia‐Mare Romania;

    Department of HematologyEmergency County HospitalBaia‐Mare Romania;

    Department of HematologyEmergency County HospitalBaia‐Mare Romania;

    Department of HematologyCol?ea Hospital Carol Davila University of Medicine and PharmacyBucharest;

    Department of HematologyUniversity Emergency Hospital Bucharest Carol Davila University of;

    Department of HematologyUniversity Emergency Hospital Bucharest Carol Davila University of;

    Department of HematologyUniversity Emergency Hospital Bucharest Carol Davila University of;

    Department of HematologyUniversity Emergency Hospital Bucharest Carol Davila University of;

    Department of Medical GeneticsIuliu Ha?ieganu University of Medicine and PharmacyCluj‐Napoca Romania;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 血液及淋巴系疾病;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号